



Top-20 AI in Drug Discovery Investors

Top-20 AI in Drug Discovery Investors

Table of Contents

Infographic Summary and Mind Maps	3	Investments Strategies	18
Executive Summary	7	Investors Classification	22
Methodology for Ranking	8	Strengths and Weaknesses	28
Investors Overview	10	Future Prospects	33
Segmentation		Conclusions	39
Comparative Analysis		Disclaimer	52
Geographical Distribution			
Investments Statistics	12		

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2019 Q1

Companies - 150
Investors - 350
Corporations - 50



Executive summary

Top-20 AI for drug discovery investors belong predominantly to the lists of the biggest and most effective global venture and investment funds that do not specialize exclusively on biotech and pharma ventures but pay high attention to this industry.

Most of the top-20 investors in AI for drug discovery are concentrated on the early stages of investment. Namely, each of the 20 funds provides early stage investment. Only 25% of investors are engaged in debt financing. However, we need to understand that the situation can be different when we observe exclusively biotech or even drug discovery investment. In this case, aforementioned investors may be relatively more conservative. Thus, the share of late-stage investments may grow.

Overall, investment activity has been steadily increasing in the pharmaceutical AI space over the previous year, judging by an increased number of investment rounds as well as total funds raised. Top-20 funds are not only leaders of investment, but in many cases also leaders of growth.

Together, these 20 firms have raised over \$40 billion, with Sequoia Capital alone accounting for roughly a third of that amount. In fact, Sequoia Capital — arguably Silicon Valley's most eminent venture capital firm, with an impressive investment record that encompasses the likes of Google, Amazon, Apple, and Cisco, just to name a few — has been heavily involved in the healthcare sector.

In the future, we can expect development and growth of specialized investment in biotech sector, which can accelerate AI for drug discovery investments even more.

It should be noted that many of top-20 AI for drug discovery investors show some similarities in their investment strategies even on the level of companies, namely Insitro, Atomwise or whoXAR are quite widespread investment targets among them.

Geographic diversity is increasing in the pharmaceutical AI industry, with more countries joining the pharmaceutical AI race and corresponding capital markets. Historically the US has been dominating the space of pharmaceutical AI — both in terms of companies and investments and industry, however, we are seeing an increased level of activity from the UK and EU. We are also seeing a dramatic increase in activity from the Asia-Pacific region generally, and from China in particular. The number of investors based in the Asia-Pacific region, including China and Singapore, increases significantly, with a slew of large investment rounds occurring in the first half of 2019 alone.

Executive summary

The entry of Chinese investors in the broader biotech and drug industry landscape mounted significantly in 2019, rising to \$1.4 billion of investments into US-based biotech and drug firms compared to just \$125.5 million during the same period the previous year. Furthermore, the Chinese government has recently shown significant interests in building up their AI industry, and in prioritizing AI in healthcare in particular. In an AI Strategic Plan released in July 2017, they outlined their intentions to catch up in the AI race by 2020, make major breakthroughs by 2025 and become the world leader in AI by 2030. Chinese IT and Tech corporations, such as Alibaba, Baidu and Tencent, have made significant investments and acquisitions in the area of pharmaceutical and healthcare AI, while also the number of Chinese investors active in this area is steadily increasing.

Among top drivers of China's march in the pharmaceutical AI race, there is, first, the ability to generate massive amounts of real-time medical data from more than 1 billion local population, stimulated by rather flexible privacy laws. Secondly, the market of Chinese AI and data science talent is rapidly growing — due to proactive government programs, and “reverse migration” of highly skilled and educated Chinese professionals from the US, UK and EU. However, China is lagging behind the Western world in terms of core pharmaceutical and biotech innovation, which will be limiting the speed of progress in the global pharmaceutical AI race. Another limiting factor is less stringent IP protection laws, compared to Western countries — newly generated innovation in pharmaceutical AI might be diffusing to competitors.

Deep learning (DL) family of algorithms become a major technology differentiator in the pharmaceutical AI race. Deep Learning in general and Generative Adversarial Networks (GANs) in particular are being increasingly regarded as a “golden standard” of innovation in the pharmaceutical AI space and important investment target.

The total valuation of the AI for Drug Discovery sub-sector grew approximately 1.5 - 2x during the last 6 months, which leads to the growth of investment volumes.

Investors Ranking Framework



General characteristics of investors

Area of investment

Marketing of investors

Financial position of investors

Methodology

The infographic dashboard on *page 6* displays geographical distribution of top-20 investors into AI-driven advanced healthcare and drug discovery companies. Top-20 Investors are mainly based in the U.S., followed by Chinese, United Kingdom and European Union companies. The infographic on *page 7* outlines the top-20 investors in top-130 AI companies operating in the field of drug discovery and similar industries during 2012-2019. The header displayed at the top of the given infographic shows the key investors, the number of investments deals they made, and the top AI-powered biopharmaceutical and biotechnology companies that obtained funding/assistance.

Data on seed rounds, private equity, corporate rounds, venture funding, grants, as well as other types of funding rounds and non-equity assistance were collected and analysed according to various parameters set forth in Deep Knowledge Analytics evaluation criteria methodology. The top-20 leading investors in AI for drug discovery and advanced health sector have been selected based primarily upon the following criteria:

- Number of investments (from 2 to 9) made in 130-AI Companies, specializing in Drug Discovery;
- The potential for equity and non-equity financing (lead investors in seed/venture rounds);
- Investors overall background, intangible assets and philosophy.

Within the framework of the given research, data related to over 500 investment deals, concluded by 320 private and corporate investors, were collected. The share of deals concluded in 2018 constituted circa 27% of the total number of investments.

The data table on *page 9* shows the top 10 smart investors in top 25 biotech, biopharmaceutical research and development and advanced healthcare. The basic criteria underpinning the selection of the top 10 investors in the aforementioned industries were as follows:


- Minimum 2 investments in the top 25 companies;
- The volume of funding/financing;
- Investors' intangible assets/capacities.

The trend is that investors keep investing several times in the same companies due to established partnerships and business models that gained credibility.

20 Leading Investors in AI for Drug Discovery Sector















































1	500 Startups	11	GV
2	Amadeus Capital Partners	12	Khosla Ventures
3	AME Cloud Ventures	13	OS Fund
4	Amgen Ventures	14	Refactor Capital
5	Andreessen Horowitz	15	Sequoia Capital
6	Data Collective DCVC	16	SOSV
7	Draper Associates	17	StartX (Stanford-StartX Fund)
8	Felicis Ventures	18	WuXi AppTec
9	Tencent	19	Y Combinator
10	General Catalyst	20	ZhenFund

Top-20 AI for Drug Discovery Investors



Top-20 Investors in 130 AI-Companies by number of investments

Top AI Companies ← Investments overall — INVESTORS — Investments overall → Top AI Companies

	9	 Y combinator	 Sequoia Capital	9	 
	8	 SOSV	 OS Fund	8	 
 	8	 GV	 Data Collective DCVC	8	 
 	8	 AME Cloud Ventures	 ZhenFund	7	
 	6	 Khosla Ventures	 Andreessen Horowitz	6	 
	6	 Amadeus Capital Partners	 WuXi AppTec	5	  
	5	 General catalyst	 StartX	4	
	4	 Refactor Capital	 Tencent	4	  
	4	 Felicis ventures	 Draper associates	4	
 	3	 Amgen ventures	 500 startups	3	


Top-20 Investors AI in Drug Discovery

Investments vs
Smart Investments

Other AI Companies

Investors

































Top-25 AI
Companies



Smart 10 Investors in Top-25 AI Companies

5 April 2019

Top AI Companies ← INVESTORS → Top AI Companies

 Atomwise	 iCarbonX	 XtalPi	 Tencent 腾讯 Tencent	 药明康德 WuXi AppTec WuXi AppTec	 Insilico Medicine 英科智能	 SCHRODINGER.	 WuXiNextCODE
	 twoAR	 insitro	 a16z Andreessen Horowitz	 GV GV	 insitro	 SCHRODINGER.	
	 WuXiNextCODE	 insitro	 ARCH VENTURE PARTNERS ARCH Venture Partners	 kv Khosla Ventures	 Atomwise	 deep genomics	
	 RECURSION pharmaceuticals	 CYCLICA	 EPIC Capital	 SEQUOIA Sequoia Capital	 XtalPi	 WuXiNextCODE	
	 RECURSION pharmaceuticals	 Atomwise	 DCVC Data Collective DCVC	 AME AME Cloud Ventures	 RECURSION pharmaceuticals	 Atomwise	

Investors Strategies

Features and elements of strategies of successful investors in AI for Drug Discovery

Companies to invest in	Big number of investment in top AI for Drug Discovery companies
	Diversification by different domains of drug discovery process
	Investment in advanced AI
Investor`s features	Combination of AI for Drug Discovery investments with other deep tech investments
	Multistage investments
	Investment volume is more than average
Tech expertise	Founders with expertise in AI and biotech
	Consulting for startups and cooperation with R&D centers
Others	Geographical and industrial diversity

What differentiates successful AI for Drug Discovery investors from unsuccessful ones? Together with common success features (diversification, quantitative metrics, deep industry analysis, risk management tools) there are some industry-specific parameters of investors behavior that contribute to the success in AI for Drug Discovery investment.

Features and elements of strategies of successful investors in AI for Drug Discovery

Lack of industry knowledge
Investment in low-level AI companies
Lack of diversification
Preference for overhyped companies
Misunderstanding of AI for Drug Discovery risks

Key Points of Analytical Report

Together, these 20 firms have raised over \$40 billion dollars, with Sequoia Capital alone accounting for roughly a third of that amount. In fact, Sequoia Capital – arguably Silicon Valley’s most eminent venture capital firm, with an impressive investment record that encompasses the likes of Google, Amazon, Apple, and Cisco, just to name a few – has been heavily involved in the healthcare sector.

In 2016, the venture capital firm was part of the second largest VC-backed M&A exit of all-time, second only to WhatsApp’s \$22 billion acquisition, when AbbVie acquired cancer drug startup Stemcentrx in April of that year for over \$10 billion; Sequoia Capital’s interest in Stemcentrx dates back to 2014, when the VC firm took part in the company’s \$200 million Series F round. In the same year, Sequoia participated in Clover Health’s \$160 million Series C round. Clover is a health insurance company that seeks to reduce healthcare costs for both patients and insurance companies by leveraging data analysis and preventative care to deduce when patients need medical treatment and then intervene in their care in a timely manner. Sequoia had also led a \$35 million Series B funding round into Clover in December 2015.

“We’ve been investing in healthcare for many years, mainly in HCIT/services and diagnostics. More recently, we’ve partnered with companies in insurance (Clover) and life sciences (Berkeley Lights, Cambridge Epigenetics, Guardant, Stemcentrx). We’re excited about Clover because we believe technology will be the key enabler of better outcomes for patients. In life sciences, we’ve followed the advances in genetics over the last 10-15 years and believe that the number of interesting applications (like gene editing and liquid biopsies), and their eventual impact on human health, is just beginning.” – Michael Dixon, Partner at Sequoia Capital.

Looking at Sequoia and Y Combinator’s investments, it becomes apparent that the former often looks to the latter for companies to invest in: As of 2016, Sequoia was an investor in 8 of Y Combinator’s top 10 most valuable alumni. And although Sequoia’s involvement in Series A rounds had been shrinking, they still represented the biggest chunk of its investment portfolio, 42% to be exact, followed by Series B stage investment, which took up 26% of the firm’s portfolio.

In its most recent Demo Day, Y Combinator 28% of the 122 involved were healthcare related, only 2% behind the leading category – B2B software and services. The seed accelerator has a rich track record in helping healthcare tech startups.

Key Points of Analytical Report

Among the startups were Bot M.D., an AI-powered chatbot that helps doctors all over the world easily access information on drug interactions, medical calculators, guidelines, protocols, and information on less common diseases, and Curebase, software that streamlines a number of tasks related to clinical trials, such as participant eligibility, enrollment, education, and consent. Historically, Y Combinator has invested in more than 180 healthcare startups, whose work involves artificial intelligence, electronic health records, clinical testing, real-time remote monitoring, big data and analytics, and the discovery and development of therapeutics to name a few.

Many of these venture funds prefer to invest with a focus on software, back-end infrastructure, infrastructure of the Internet, cloud computing, enterprise software and services, consumer, business Internet, mobile-Internet, consumer Internet, cloud computing, data storage, social network browsers data-storage, consumer electronics, networking functions etc. Biotech and drug discovery, in particular, are relatively new fields for them. Of course, as it was previously mentioned, a lot of healthcare startups were already in the portfolios of the funds, but such startups were often just IT applications for healthcare services. But drug discovery is where IT meets biotech.


We can observe more investment in software related biology, biotech, and medicine companies at the intersection of computer science and life sciences.

However, even now, there are specialized investment companies that are focused predominantly on the life science industry. For example, Amgen Ventures invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. Small venture funds, obviously, can benefit from their proficiency in specific areas of knowledge.

Main Fields of Investment

Company name	AI	Finances	Media & Internet	Healthcare	Big data	IT
Sequoia Capital	•	•	•	•		•
Andreessen Horowitz	•		•	•	•	•
Felicis Ventures	•	•		•		•
Draper Associates	•	•	•			•
Khosla Ventures	•		•			•
Amgen Ventures	•			•		•
Data Collective DCVC	•				•	•
Founders Fund	•		•	•		•
500 Startups	•		•			•
Y Combinator	•			•		•
GV	•			•	•	•
StartX	•	•	•	•	•	•
AME Cloud Ventures	•	•		•	•	•
Refactor Capital	•	•		•		•
OS Fund	•			•		•
General Catalyst	•		•	•	•	•
SOSV	•			•		•
WuXi AppTec	•			•		•
ZhenFund	•	•	•	•		•
Amadeus Capital Partners	•	•	•	•		•
Tencent Holdings	•		•		•	•

Level of Overall Investment Activity



Leaders
(as of February 2019)

Y Combinator

500 Startups


Sequoia Capital

Source

Crunchbase

Investments Structure

Although the percentage of investments in AI remains low in comparison with investment in software, on the graph below we can see one company, which invests more in AI (in particular over 8% of investments), rather than in software – it is Chinese ZhenFund. Chinese corporations, in the past several years, have definitely earned a reputation of innovators, funding the most perspective and advanced segments, consequently moving up in Global Innovation Ranking to the top 20 innovative countries. This may show the global trend and the point, that future investments in AI will only be growing. Growing share of AI investment will likely correlate with the growth of AI for drug discovery investment.



Source

Crunchbase

Common Features of Top-20 Investors

In order to understand the specifics of AI for drug discovery investment of top-20 funds, we need to investigate their common features in general, namely their investment behavior, strategies and preferences. It is crucial to note that the vast majority of the portfolio of such funds consist of IT companies. Traditionally top venture funds were not eager to invest large shares of capital in biotech, but AI in drug discovery can become a bridge that connects tech venture capital with the modern biotech industry.

Most of companies invest in
Software, IT and Internet


Investments in AI are
significant only for 45% of
companies

The percentage of
investments in AI is
remaining low (especially in
comparison with Software)

StartX is the leader in AI
investments volume


AI for Drug Discovery Investments

The diagram below indicates an overall number of AI for drug discovery investments of 20 leading companies in the given industry. The first position is, obviously, occupied by two biggest leaders in the whole industry – Sequoia Capital and Y Combinator. Both of them had 9 separate investment events. The second position is divided between slightly smaller companies, such as AME Cloud Ventures, Data Collective DCVC, GV, DS Fund and SOSV. All of them invested in AI for drug discovery 8 times. Last 3 positions were taken by the following companies: 500 Startups, Amgen Ventures



Total Funds Raised


The graph below* demonstrates two undoubtable leaders in raising funds in AI for drug discovery segment. Among them is an aforementioned Sequoia Capital, with an indicator near \$1,5 billion, which is a third of total amount raised. Second company in this list is AME Cloud Ventures, which raised nearly \$1,2 billion. The top-5 is closed by three following companies: Andreessen Horowitz, General Catalyst and Founders Fund.



* Information on Tencent is not available.

Annual Revenue


The comparison of companies' annual revenue below allows us to see, that first three positions belong to the following companies: Tencent Holdings (44,4 \$b), SOSV and Andreessen Horowitz. These indicators are quite interesting, because companies, which invest the most in AI in drug discovery, such as Andreessen Horowitz, don't get the most revenue. Instead, SOSV, which invested much less than aforementioned organizations, gets the first position. This may possibly be explained by the Law of Diminishing Returns as well as other different factors. Tencent is not listed on the picture due to the visualization purposes.



Source


owler.com

Type of Investment Stage



It is quite obvious that most of the top-20 investors in AI for drug discovery are concentrated on the early stages of investment. Namely, each of the 20 funds provides early stage investment. Only 25% of investors are engaged in debt financing. However, we need to understand that the situation can be different when we observe exclusively biotech or even drug discovery investment. In this case, aforementioned investors may be relatively more conservative. Thus, the share of late-stage investments may grow.


Investors by Regions



This diagram illustrates the location of the top investors in AI for drug discovery leaders across the globe. The USA and Great Britain remain home for the largest number of investment funds. However, we can already observe increasing role of China that has the potential to substantially alter these statistics in the coming years due to capital flows from the USA and Europe.

How are Investors Healthcare-Oriented? (Q1 2014 - Q1 2019)

The graph below reveals the situation in healthcare investment segment. The first position is, as almost always, held by a stable leader in investment amounts – Sequoia Capital, with a total amount of \$2 billion. Next three positions' indicators are very close to each other and are represented by the following organizations: Founders Fund, Khosla Ventures and Amgen Ventures, with amounts close to \$1 billion. The lowest positions are occupied by Draper Associates, ZhenFund and 500 Startups, which obviously prefer other investment spheres, rather than healthcare.



AI for Drug Discovery Investment Specifics


DRUG DEVELOPMENT	DATA AGGREGATION & ANALYSIS	CLINICAL TRIAL DESIGN, OPTIMIZATION, RECRUITMENT
Andreessen Horowitz	Khosla Ventures	Sequoia Capital
Felicis Ventures	Founders Fund	Amadeus Capital Partners
Draper Associates	GV	
Y Combinator	ZhenFund	
StartX	Tencent	
AME Cloud Ventures		
OS Fund		
WuXi AppTec		

500 Startups


500 Startups is a global venture capital seed fund with a network of startup programs headquartered in Silicon Valley and is the #1 most active seed fund in the world.

500's mission is to discover and back the world's most talented entrepreneurs, help them create successful companies at scale, and build thriving global ecosystems. Since its inception, 500 Startups have made it its mission to find and empower talented founders, whether they're across the world or overlooked in its own backyard.

500 Startups typically invest between \$25K-\$250K USD in its first check, however, they also make selective follow-on investments at Series A/B of up to \$1M USD. 500 Startups is based in San Francisco, California but its companies, mentors, and advisers come from 60+ countries around the world.



500 Startups



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
BenchSci	Series A	2018	N/A
Transcriptic	Series A	2015	8.5
uBiome	Product Crowdfunding	2013	0.351

Amadeus Capital Partners

Amadeus Capital Partners is a global technology investor. Since 1997, the firm has backed more than 130 companies and raised over \$1bn for investment. Amadeus Capital Partners invests in consumer services, financial technology, artificial intelligence, cybersecurity, medical technology, digital health and digital media.


Pioneering businesses they've backed include gene-sequencing innovators Solexa, massively parallel simulation platform Improbable.io, cybersecurity vendor ForeScout, Optos, producer of advanced retinal imaging, and Kreditech, provider of financial products to the 'underbanked'. Amadeus Capital Partners offers over 20 years' experience in technology investment. They invest across the world, from their bases in Bangalore, Cambridge, Cape Town, London and San Francisco. They focus on early stage, primary and secondary growth capital and emerging markets.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Antidote	Series A	2013	3.2
Antidote	Series B	2015	13.5
Antidote	Venture Round	2011	1.2
Healx	Series A	2018	10
Healx	Seed Round	2016	1.8
Synthace	Series A	2017	9.1



Amadeus
Capital Partners

Amadeus Capital Partners



AME Cloud Ventures


AME Cloud Ventures is the venture fund led by Jerry Yang, co-founder of Yahoo! AME Cloud Ventures focuses on seed to later stage companies building infrastructure and value chains around data. AME Cloud Ventures loves technology-heavy companies gathering or creating unique data at every stage of the data stack — from infrastructure all the way to applications, mobile, and sensors.

AME Cloud Ventures strive to find, fund, and support true entrepreneurs. They provide a unique and genuine set of resources to their founding teams, from strong operational and business experience to networks of amazing mentors and international partners, particularly China. 'Ame', pronounced 'ah-may', means rain in Japanese - a reflection on our belief that accurate, actionable data will be a major life-blood in the future economy.

AME

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Seed Round	2015	6
Cambridge Cancer Genomics	Seed Round	2018	4.5
BioAge Labs	Series A	2017	10.9
Recursion Pharmaceuticals	Series A	2016	2.2
Recursion Pharmaceuticals	Series A	2016	12.9
Transcriptic	Venture Round	2016	13.4
Transcriptic	Series A	2015	8.5
Transcriptic	Seed Round - Transcriptic	2014	2.8

AME Cloud Ventures




Amgen ventures

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later-stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In discovery research and technology, the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between \$2 million and \$3 million per transaction and may invest up to \$10 million per company. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
GNS Healthcare	Venture Round	2017	6
WuXi NextCODE	Series B	2017	75
Cytos	Post IPO Equity	2012	40

AMGEN Ventures




Andreessen Horowitz

Andreessen Horowitz LLC is a venture capital firm specializing in investing in seed, start-ups, early, mid-stage, growth, and late stage. It prefers to invest in the social media business and technology sector with a focus on software, back-end infrastructure, infrastructure of the Internet, cloud computing, enterprise software and services, consumer, business Internet, mobile-Internet, consumer Internet, cloud computing, data storage, social network browsers data-storage, consumer electronics, networking functions, software related biology, biotech, and medicine companies at the intersection of computer science and life sciences with a focus on digital therapeutics, cloud technology in biology, and computational medicine.

ANDREESSEN
HOROWITZ

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
BioAge Labs	Series A	2017	10.9
Insitro	Series A	2018	N/A
TwoXAR	Series A	2018	10
TwoXAR	Seed Round	2015	3.4
uBiome	Series A	2014	4.5




Data Collective DCVC

Data Collective is a venture fund with a unique team of experienced venture capitalists, technology entrepreneurs and practicing engineers, investing together in seed and early-stage Big Data and IT infrastructure companies.


Data Collective's leaders have been investing for two decades, with over 150 companies still going strong and 40 material exits to date for entrepreneurs and investors.

The firm brings to bear more than 35 experienced technology executives and experts (CTOs, CIOs, Chief Scientists, Principal Engineers, Professors at Stanford and Berkeley) with significant tenures at institutions ranging from Akamai to Zynga.



Data Collective DCVC

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Seed Round	2015	6
Atomwise	Series A	2018	45
Recursion Pharmaceuticals	Series B	2017	60
Recursion Pharmaceuticals	Series A	2016	2.2
Recursion Pharmaceuticals	Series A	2016	12.9
Transcriptic	Venture Round	2016	13.4
Transcriptic	Series A	2015	8.5
Transcriptic	Seed Round	2014	2.8



Draper Associates


Draper Associates is a seed stage venture fund in Menlo Park, CA. Draper Associates invest globally, in great teams of people creating revolutionary companies in new media, gaming, SaaS, cloud, new finance, IOT, and mobile.

Draper Associates typically invest in the earliest round, in syndicate with other sophisticated investors. They are comfortable leading in dollars and terms, or participating. They are venture advisers: help where and when asked to get their companies to the next stage of growth, otherwise stay out of the entrepreneurs' way. While each investment is unique, Draper Associates often help their company's with business development, later stage capital raising, strategy, hiring, employee options, valuations, and M&A.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Seed Round	2015	6
CloudMedX	Venture Round	2017	5.3
Verge Genomics	Seed Round	2015	4



Draper Associates



Felicis Ventures


Founded in 2006, Felicis Ventures is a boutique venture capital firm based in Menlo Park. They invest in iconic companies reinventing core markets (Adyen, Credit Karma, Clearslide, Rovio, Shopify), as well as those creating frontier markets (Guardant Health, Fitbit, Gingko Bioworks, Planet Labs, Vicarious).

More than 70 Felicis portfolio companies have exited, including Meraki (acquired by Cisco), Twitch (acquired by Amazon), Brightroll (acquired by Yahoo), Dropcam (acquired by Google), Ring (acquired by Amazon), Shopify (NYSE:SHOP), Fitbit (NYSE:FIT), Rovio (HEL:ROVIO), Pluralsight (NASDAQ:PS), and Adyen (AMS: ADYEN).

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
BioAge Labs	Series A	2017	10.9
Recursion Pharmaceuticals	Series B	2017	60
Recursion Pharmaceuticals	Series A	2016	2.2
Spring Discovery	Series A	2018	18



Felicis Ventures




Tencent Holdings

Founded in November 1998, Tencent is a leading provider of Internet value-added services in China. Since its establishment, Tencent has maintained steady growth under its user-oriented operating strategies. It is Tencent's mission to enhance the quality of human life through Internet services. Presently, Tencent provides social platforms and digital content services under the "Connection" Strategy. The development of Tencent has profoundly influenced the ways hundreds of millions of Internet users communicate with one another as well as their lifestyles. It also brings possibilities of a wider range of applications to China's Internet industry. With its R&D staff comprising more than 60% of its employee base, Tencent has obtained patents relating to technologies in various areas such as instant messaging, e-commerce, online payment services, search engine, information security, gaming, and many more.

Tencent 腾讯

Tencent Holdings



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Series A	2018	45
iCarbon X	Series A	2016	155
XtalPi	Series B	2018	15

General Catalyst


General Catalyst is a venture capital firm that makes early-stage and transformational investments. General Catalyst backs exceptional entrepreneurs who are building innovative technology companies and market-leading businesses, including Airbnb, BigCommerce, ClassPass, Datalogix, Datto, Demandware, Gusto (fka ZenPayroll), The Honest Company, HubSpot, KAYAK, Oscar, Snap, Stripe, and Warby Parker.

The General Catalyst team leverages its broad experience to help founders build extraordinary companies. General Catalyst has offices in Cambridge, MA, Palo Alto, CA and New York City. General Catalyst has managed eight venture capital funds totaling approximately \$3.75 billion in capital commitments.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
PathAI	Series A	2017	11
Spring Discovery	Series A	2018	18
Spring Discovery	Seed Round	2018	4.3
PathAI	Series A	2017	11



General Catalyst



GV


Launched as Google Ventures in 2009, GV is the venture capital arm of Alphabet, Inc. They've invested in more than 300 companies that push the edge of what's possible. In the fields of life science, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture, their companies aim to improve lives and change industries.

They've built a team of world-class engineers, designers, physicians, scientists, marketers, and investors who work together to provide these startups with exceptional support on the road to success. They help their companies interface with Google, providing unique access to the world's best technology and talent.



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Celsius Therapeutics	Series A	2018	65
Insitro	Series A	2018	N/A
Owkin	Series A	2018	5
Transcriptic	Seed Round	2014	2.8
Transcriptic	Seed Round	2012	1.2
ZappRx	Series B	2017	25
Schrodinger	Series E	2019	85

GV




Khosla Ventures

Khosla Ventures is a venture capital firm that started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm focuses on environmentally friendly technologies in addition to the traditional venture areas. With over five billion dollars under management, the firm focuses on a broad range of areas including consumer, enterprise, education, advertising, financial services, semiconductors, health, big data, agriculture/food, sustainable energy and robotics. Khosla Ventures is headquartered in Menlo Park, Calif.

khosla ventures

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Seed Round	2015	6
Atomwise	Series A	2018	45
Deep Genomics	Series A	2017	13
ThoughtSpot	Series D	2018	145
ThoughtSpot	Series C	2016	50
ThoughtSpot	Series B	2014	30




OS Fund



OS Fund invests in entrepreneurs using applied intelligence to commercialize breakthrough discoveries in genomics, synthetic biology, diagnostics, new materials development and energy. OS Fund seeks out platform enabling technologies that accelerate discovery and commercialization. OS Fund never invests in a single molecule, model or algorithm. They do hard science investing with technology level risk. They work with their portfolio companies to develop foundational IP that solves real-world challenges and paves a path for commercialization. OS Fund has thoughtfully constructed a cross-disciplinary group of companies that are each uniquely contributing to the robust ecosystem they all need to thrive.

Four years later, OS Fund performance is in the top decile among U.S. firms. Of the 28 investments, OS Fund has 4 unicorns, 26 up valuations, and 2 acquisitions.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Atomwise	Seed Round	2015	6
Emerald Cloud Lab	Series C	2015	20.5
TwoXAR	Series A	2018	10
uBiome	Series C	2018	83
uBiome	Series A	2014	4.5
uBiome	Seed Round	2014	N/A
Verge Genomics	Series A	2018	32
Verge Genomics	Seed Round	2015	4




Refactor Capital

Refactor Capital is a \$50M early-stage venture capital firm that invests in founders tackling problems in hard but not impossible areas such as applied biology, healthcare, crypto, food, wellness, transportation, aerospace, and more. Refactor Capital invests primarily in seed-stage companies, helping define go-to-market strategies and navigate the various challenges founders encounter. Refactor Capital prefers using their Series Seed docs when leading a round but remains flexible.

Refactor Capital believes that the most valuable opportunity set for startups in the next few decades will be the creative destruction of the status quo in industries that have so far resisted innovation. The way to get there might be different, but these areas are unexceptional in one important aspect: they will yield to progress like all other industries before them.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Cambridge Cancer Genomics	Seed Round	2018	4.5
PathAI	Series A	2017	11
PathAI	Venture Round	2016	4.2
Verge Genomics	Seed Round	2015	4




Sequoia Capital

From idea to IPO and beyond, the Sequoia team helps a small number of daring founders build legendary companies. Sequoia Capital spurs them to push the boundaries of what's possible. In partnering with Sequoia, companies benefit from their unmatched network and the lessons they've learned over 45 years working with Steve Jobs, Larry Ellison, John Morgridge, Jerry Yang, Elon Musk, Larry Page, Jan Koum, Brian Chesky, Drew Houston, Adi Tatarko and Jack Dorsey, among many others. In aggregate, Sequoia-backed companies account for more than 20% of NASDAQ's total value. Sequoia Capital is proud that their success also fuels great causes. The vast majority of money they invest is on behalf of non-profits and schools like the Ford Foundation, Mayo Clinic and MIT, which means that the returns generated from the incredible achievements of founders can make a massive difference.



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Athelas	Seed Round	2017	3.5
Berkeley Lights	Series C	2015	56.5
Berkeley Lights	Series D	2018	95
WuXi NextCODE	Series C	2018	200
WuXi NextCODE	Series B	2017	165
XtalPi	Series B	2018	15
PatSnap	Series D	2018	38
Deep Intelligent Pharma	Series B	2019	15

Sequoia Capital




SOSV

SOSV runs the world's leading accelerator programs in hardware, life sciences, cross-border internet/mobile in Asia, food, and blockchain. SOSV has >\$525M in assets under management and provides seed, venture, and growth-stage funding to startups. Their market-specific accelerator programs are located in the US, Asia, and Europe. The firm has a staff of over 90 worldwide, and 620+ global mentors. SOSV is headquartered in Princeton, New Jersey with offices in San Francisco, New York, Cork, Boston, Shenzhen, Shanghai, London and Taipei. Over the past 20 years, the firm has funded well over 600 startups and currently to fund over 150 startups per year. All startups are funded initially through SOSV accelerators. SOSV invests substantial effort in social innovation and transformation in various fields, especially in education and computing, where the company and its staff have supported or founded such initiatives as Coderdojo, Open Ireland, Mathletes, Khan Academy, WeForest and more.



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
A2A Pharmaceuticals	Seed Round	2016	N/A
Mendel.ai	Seed Round	2017	2
Mendel.ai	Convertible Note	2016	N/A
Mendel.ai	Seed Round	2016	N/A
Synthace	Series B	2018	25.6
Synthace	Series A	2018	N/A
Synthace	Series A	2017	9.2
Synthace	Series A	2014	2.7




StartX (Stanford-StartX Fund)

StartX is a Stanford-affiliated nonprofit in Silicon Valley that runs one of the world's top startup accelerator programs. Their mission is to advance the development of the best entrepreneurs through experiential education and peer learning. Since launching in 2010, they have supported more than 450 companies and 1000 entrepreneurs, from early to the pre-IPO stage, working across a wide spectrum of industries. StartX and StartX Med, dedicated to medical and biotechnology innovation, provide founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. Based in Palo Alto, the accelerator also operates StartX-QB3 Labs and the Stanford-StartX Fund. They are funded by Stanford University, Stanford Health Care, Microsoft, Steelcase, Hyundai, Oriza Ventures, Nissan, Panasonic, Lightspeed Venture Partners, Analog Devices, Silicon Valley Bank, Greylock Partners, Sequoia Capital, and many others.



StartX



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Globavir	Venture Round	2015	4
NuMedii	Series A	2015	2
TwoXAR	Seed Round	2015	3.4
uBiome	Series B	2016	22

WuXi AppTec


WuXi AppTec Group is a leading pharmaceutical, biopharmaceutical, and medical device capability and technology platform company with 16,000 employees globally, including more than 13,000 dedicated scientists. Through its 28 R&D sites worldwide, and a total of 6.0 million square feet of office, laboratory and manufacturing space, WuXi Group provides comprehensive platform capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics.

Today, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients.

COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Engine Biosciences	Seed Round	2018	10
Insilico Medicine	Series A	2018	6
Transcriptic	Venture Round	2016	13.4
Verge Genomics	Series A	2018	32
Schrodinger	Series E	2019	85



WuXi AppTec




Y Combinator

Y Combinator is a startup accelerator based in Mountain View, CA. In 2005, Y Combinator developed a new model of startup funding. Twice a year they invest a small amount of money (\$120K) in a large number of startups. The startups move to Silicon Valley for 3 months. The YC partners work closely with each company to get them into the best possible shape and refine their pitch to investors. Each cycle culminates in Demo Day when the startups present their business plans to a carefully selected, audience of investors. All venture investors supply some combination of money and help. In Y Combinator's case, the money is by far the smaller component. In fact, many of the startups they fund don't need the money. Y Combinator thinks of the money they invest as more like financial aid in college: it's so people who do need the money can pay their living expenses while Y Combinator is happening.



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Athelas	Seed Round	2017	3.5
Atomwise	Series A	2018	45
Atomwise	Seed Round	2015	6
Cambridge Cancer Genomics	Seed Round	2018	4.5
Reverie Labs	Seed Round	2018	N/A
Transcriptic	Seed Round	2014	0.12
uBiome	Series C	2018	83
uBiome	Series A	2014	4.5
Verge Genomics	Seed Round	2015	0.12

Y Combinator




ZhenFund

ZhenFund is a seed stage focused venture fund founded in 2011 by Bob Xu and Victor Wang, in collaboration with Sequoia Capital China. Bob and Victor previously co-founded New Oriental (NYSE: EDU), one of the world's largest education conglomerates. Three of Bob's seed investments have IPOed in NYC: Shiji Jiayuan (Nasdaq: DATE), LightInTheBox (Nasdaq: LITB) and Jumei (NYSE: JMEI). In 2016, Bob was honored on the Midas List as one of the top 100 tech investors. ZhenFund currently dominates China's early-stage venture capital scene and is rapidly expanding its U.S. practice based in Palo Alto, CA. Its portfolio has over 150 high-growth companies, including 17zuoye, OFO, VIPKID, RED, Hero Entertainment, and Urwork. ZhenFund's mission is to support, educate, and inspire the next generation of global entrepreneurs.



COMPANY NAME	FUNDING ROUND	YEAR	AMOUNT, MLN \$
Deep Intelligent Pharma	Series A	2018	6.6
Deep Intelligent Pharma	Seed Round	2017	N/A
Spring Discovery	Series A	2018	18
Transcriptic	Venture Round	2016	13.4
uBiome	Series B	2016	22
XtalPi	Series A	2016	1.1

ZhenFund



Appendix: List of 320 AI for Drug Discovery Investors

- | | | |
|-------------------------------------|-------------------------------------|------------------------------------|
| 1. 10x Group | 28. B Capital Group | 55. Celgene |
| 2. 11.2 Capital | 29. Baidu Ventures | 56. China Bridge Capital |
| 3. 500 Startups | 30. Baird Capital | 57. China Equity |
| 4. 6 Dimensions Capital | 31. Bakken & Baeck | 58. Citrix Startup Accelerator |
| 5. 8VC | 32. Balderton Capital | 59. Citrix Systems |
| 6. A-Level Capital | 33. Baron Capital Management | 60. Claremont Creek Ventures |
| 7. Accelerate Long Island | 34. Basis Set Ventures | 61. Clarus Ventures |
| 8. Accelerate@Babraham | 35. BDC Venture Capital | 62. CLI Ventures |
| 9. Advantage Capital | 36. Beast Ventures | 63. Cota Capital |
| 10. Afore Capital | 37. Bill & Melinda Gates Foundation | 64. Creative Destruction Lab |
| 11. Agent Capital | 38. Bioeconomy Capital | 65. Crowdcube |
| 12. AGORANOV | 39. Biomatics Capital Partners | 66. CrunchFund |
| 13. Alexa Fund | 40. Bios Partners | 67. CRV |
| 14. Alexandria Real Estate Equities | 41. Black Diamond Ventures | 68. Cultivian Sandbox Ventures |
| 15. AllBright | 42. Bloomberg Beta | 69. Danhua Capital |
| 16. Alphabet | 43. Bold Capital Partners | 70. Darling Ventures |
| 17. ALS Investment Fund | 44. BootstrapLabs | 71. Data Collective |
| 18. Amadeus Capital Partners | 45. Boundary Capital Partners LLP | 72. DCM Ventures |
| 19. AME Cloud Ventures | 46. BR Ventures | 73. Deep Knowledge Ventures |
| 20. Amgen Ventures | 47. Caffeinated Capital | 74. Deerfield |
| 21. Amplify Partners | 48. Calculus Capital | 75. Density Ventures |
| 22. Andreessen Horowitz | 49. Cambia Health Solutions | 76. Dentsu |
| 23. Aquarius Equity Partners | 50. Capital One Growth Ventures | 77. DFJ Growth |
| 24. ARCH Venture Partners | 51. Cascade Investment | 78. DHVC (Digital Horizon Capital) |
| 25. Atinum Investment | 52. Casdin Capital | 79. Digital Science |
| 26. Atlas Venture | 53. Catapult Ventures | 80. DNA Capital |
| 27. Aurinvest | 54. Cathay Innovation | |

Appendix: List of 320 AI for Drug Discovery Investors


81.	Dolby Family Ventures	108.	Foundation Capital	135.	Health Wildcatters
82.	Dorm Room Fund	109.	FounderFuel	136.	Healthbox
83.	Draper Associates	110.	Founders Factory	137.	Heritage Provider Network
84.	Draper Dragon	111.	Founders Fund	138.	Hewlett Packard Pathfinder
85.	Dynamk Capital	112.	Frazier Healthcare Partners	139.	HIGHLINEvc
86.	EASME - EU Executive Agency for SMEs	113.	FREES FUND	140.	Holtzbrinck Digital
87.	EDBI	114.	Frontier IP Group plc	141.	Horizons Ventures
88.	Emerge Education	115.	FundersClub	142.	IA Ventures
89.	Empire State Development	116.	Future Fund	143.	IDG Capital
90.	Endure Capital	117.	General Catalyst	144.	iGan Partners
91.	Enterprise Ireland	118.	Geodesic Capital	145.	Illumina
92.	Entrepreneur First	119.	GlaxoSmithKline	146.	Imperial Create Lab
93.	EPIC Capital	120.	GM&C Life Sciences Fund	147.	INDEX: Design to Improve Life
94.	EPIC Ventures	121.	Golden Venture Partners	148.	Indie Bio
95.	Esperante Ventures	122.	Goldman Sachs	149.	Initialized Capital
96.	European Investment Bank (EIB)	123.	Gradient Ventures	150.	iNovia Capital
97.	European Union	124.	Gradient Ventures	151.	IQ Capital Partners LLP
98.	Evotec	125.	Grand Central Tech	152.	Ireland Strategic Investment Fund
99.	Fairhaven Capital Partners	126.	Grand Challenges Canada	153.	J. Hunt Holdings
100.	Faridan	127.	Great Oaks Venture Capital	154.	Jiantou Huawei Investment
101.	Felicis Ventures	128.	Green Park & Golf Ventures	155.	Juvenescence
102.	Fifty Years	129.	GreenSky Capital	156.	Kakao Ventures
103.	Finance Wales	130.	GT Healthcare Capital Partners	157.	Kapor Capital
104.	First Round	131.	GV	158.	Karlin Ventures
105.	First Star Ventures	132.	Hacking Health Accelerator	159.	KdT Ventures
106.	Fly Ventures	133.	Hanhai Studio	160.	Khosla Ventures
107.	Foresite Capital	134.	HCS Beteiligungsgesellschaft		

Appendix: List of 320 AI for Drug Discovery Investors

- | | | |
|---------------------------------------|--|-------------------------------------|
| 161. Kima Ventures | 188. Merck Global Health Innovation Fund | 215. Parinvest |
| 162. Kleiner Perkins Caufield & Byers | 189. Mercury Fund | 216. Pavilion Capital |
| 163. KTB Network | 190. Midven | 217. Pear Ventures |
| 164. Lansdowne Partners | 191. Mission and Market | 218. Pentech Ventures |
| 165. Lanza Tech Ventures | 192. MIT delta | 219. Perivoli Innovations |
| 166. LaunchCapital | 193. MITS Fund | 220. Pi Campus |
| 167. LB Investment | 194. Mitsui & Co | 221. Pillar Companies |
| 168. LeFrak | 195. Monsanto Growth Ventures (MGV) | 222. Pitch@Palace |
| 169. Life Sciences Angel Network | 196. Mubadala Investment Company | 223. PivotNorth Capital |
| 170. Lightspeed Venture Partners | 197. National Institutes of Health | 224. Plug and Play |
| 171. Lilly Ventures | 198. National Science Foundation | 225. Polaris Partners |
| 172. Linden Mobile Ventures | 199. NDRC | 226. Pritzker Group Venture Capital |
| 173. Liquid2 Ventures | 200. Nest.Bio Ventures | 227. Qiming Venture Partners |
| 174. London Co-Investment Fund | 201. Nesta Ventures | 228. Qualgro VC |
| 175. Lucas Venture Group | 202. New Leaf Venture Partners | 229. Real Ventures |
| 176. Luminous Ventures | 203. New Protein Capital | 230. Redalpine Venture Partners |
| 177. Lundbeck | 204. New Wave Ventures | 231. Redmile Group |
| 178. Lux Capital | 205. New York State | 232. Refactor Capital |
| 179. Marathon Venture Capital | 206. NewDo Venture | 233. Renren Inc. |
| 180. Masa Life Science Fund | 207. Nex Cubed | 234. Rho Canada Ventures |
| 181. MassChallenge | 208. Nikon | 235. Rivas Capital |
| 182. MassDevelopment | 209. NJF Capital | 236. Roivant Sciences |
| 183. Matrix Capital Management | 210. Obvious Ventures | 237. Romulus Capital |
| 184. Matrix Partners | 211. Octopus Ventures | 238. Rough Draft Ventures |
| 185. Mayo Clinic | 212. OS Fund | 239. Sapphire Ventures |
| 186. MedTech Innovator | 213. Otium Capital | 240. SciFi VC |
| 187. Menlo Ventures | 214. Palm Drive Capital | |


Appendix: List of 320 AI for Drug Discovery Investors

- | | | |
|--------------------------------------|--|--------------------------------------|
| 241. Seneca Partners | 268. Sutter Hill Ventures | 295. Unshackled Ventures |
| 242. Sequoia Capital | 269. SV Angel | 296. UpHonest Capital |
| 243. Sequoia Capital China | 270. SV Tech Ventures | 297. Upsher Smith Laboratories |
| 244. Seraph Group | 271. SyndicateRoom | 298. Vanguard Atlantic |
| 245. Serena Capital | 272. Techammer | 299. Versant Ventures |
| 246. ServiceNow | 273. Techstars | 300. Vertex Ventures |
| 247. Shasta Ventures | 274. TECHU | 301. Village Global |
| 248. Shunwei Capital | 275. TechU Angels | 302. VisVires New Protein |
| 249. Silicon Badia | 276. Temasek Holdings | 303. VTF Capital |
| 250. Silicon Valley Bank | 277. Tencent Holdings | 304. Walden Riverwood Ventures |
| 251. Sky Ventures Group | 278. TenOneTen Ventures | 305. Walking Ventures |
| 252. Slow Ventures | 279. The Cedars-Sinai Accelerator | 306. Warburg Pincus |
| 253. Smedvig Capital | 280. The Column Group | 307. Western Technology Investment |
| 254. Sofinnova Partners | 281. The Longevity Fund | 308. White Cloud Capital |
| 255. Softbank Ventures Korea | 282. The Thiel Foundation | 309. WI Harper Group |
| 256. Sorrento Therapeutics | 283. Third Kind Venture Capital | 310. Wild Basin Investments |
| 257. SOSV | 284. Third Rock Ventures | 311. Woodford Investment Management |
| 258. Square 1 Bank | 285. TIPS | 312. WorldQuant Ventures LLC |
| 259. SR One | 286. Tribeca Venture Partners | 313. Wren Capital |
| 260. Stage Venture Partners | 287. Trinitas Capital | 314. WuXi AppTec |
| 261. Starlight Ventures | 288. True Ventures | 315. Y Combinator |
| 262. StartUp Health | 289. Truffle Capital | 316. Yael Capital Management Limited |
| 263. StartX | 290. TSVC (formerly TEEC Angel Fund) | 317. YF Capital (Yunfeng Capital) |
| 264. StartX (Stanford-StartX Fund) | 291. Two Sigma Ventures | 318. Yuansheng BioVenture |
| 265. Summit Partners | 292. uBiome | 319. ZhenFund |
| 266. Susa Ventures | 293. UK Innovation & Science Seed Fund | 320. Zhongyuan Union Cell & Gene Eng |
| 267. Susquehanna International Group | 294. Uni-Innovate Group | |



**DEEP
KNOWLEDGE
ANALYTICS
PHARMA DIVISION**

www.ai-pharma.dka.global



Link to the Report: <https://www.ai-pharma.dka.global/ai-friendly-ceos-board-members>

E-mail: pharma@dka.global

Website: ai-pharma.dka.global



Deep Knowledge Analytics (DKA) Disclaimer.

The information and opinions in this report were prepared by Deep Knowledge Analytics. The information herein is believed by DKA to be reliable but DKA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DKA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of DKA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DKA and are subject to change without notice. DKA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.

Показать в какие они инвестировали компании из Enhanced Analysis

Investor Profile Template

The profile template below illustrates a brief picture of the analysis of a investor’s current position in the AI for Drug Discovery investment landscape. Each profile serves as a visual comparative executive summary of the investor’s activities in this sphere, and will be accompanied by a deeper analysis of these metrics.



Investment strategy specifics

- Key differentiations from other funds
- Preferred domains of AI for Drug Discovery process
- Investment style and its relation to the investment in AI for Drug Discovery